Approved by Greek Health Authorities and produced by top-rated manufacturers in Greece for EU-wide distribution.
All our generic medicines are approved by the Greek Health Authorities for production and sale in Greece and other EU countries, and are produced by top-rated manufacturers in Greece.
Active Substance: Levocarnitine
| Company | Iasimo Ltd |
| Dosage Form | Oral Solution (ORAL SOL) |
| Strength | 200 mg/ml |
| Route of Administration | Oral |
| Pharmacological Class | Other Alimentary Tract and Metabolism Products |
| Packaging | BTx10x10MLx2gl |
L-Carnitine is present as a natural constituent in animal tissues, micro-organisms and plants. In man the physiological metabolic requirements are met both by the consumption of food containing carnitine and the endogenous synthesis in the liver and kidneys from lysine with methionine serving as the methyl donor. Only the L-isomer is biologically active, playing an essential role in lipid metabolism as well as in the metabolism of ketone bodies as branched-chain amino acids.
Levocarnitine liquid is indicated for the treatment of primary and secondary carnitine deficiency in adults and children over 12 years of age.
Active Substance: Calcitonin Salmon
| Company | Iasimo Ltd |
| Dosage Form | Nasal Spray Solution (NASPR.SOL) |
| Strength | 200 IU/Dose |
| Route of Administration | Nasal Use |
| Pharmacological Class | Anti-Parathyroid Agents |
Calcitonin acts primarily on bone, but direct renal effects and actions on the gastrointestinal tract are also recognised. Calcitonin-salmon appears to have actions essentially identical to calcitonins of mammalian origin, but its potency per mg is greater and it has a longer duration of action. The actions of calcitonin on bone and its role in normal human bone physiology are still not completely elucidated, although calcitonin receptors have been discovered in osteoclasts and osteoblasts.
Calcitonin salmon nasal spray is indicated for the treatment of postmenopausal osteoporosis in females greater than 5 years postmenopause with low bone mass relative to healthy premenopausal females.
All products in our generic range are fully approved by the Greek Health Authorities (EOF) and comply with EU regulatory requirements, enabling seamless distribution across EU member states and beyond.
Our generics meet all EU directive requirements, ensuring full market authorisation and traceability throughout the supply chain.
Produced exclusively by leading Greek pharmaceutical manufacturers with internationally recognised GMP certifications.
Backed by Iasimo's international logistics network, our generic products reach markets across Europe, EMEA, and beyond.
Contact our team to discuss availability, licensing, and distribution arrangements for your market.